ES2071428T3 - Derivados de (((2-amino-3,4-dioxo-1-ciclobuten-1-il)amino)alquil)acido. - Google Patents

Derivados de (((2-amino-3,4-dioxo-1-ciclobuten-1-il)amino)alquil)acido.

Info

Publication number
ES2071428T3
ES2071428T3 ES92300472T ES92300472T ES2071428T3 ES 2071428 T3 ES2071428 T3 ES 2071428T3 ES 92300472 T ES92300472 T ES 92300472T ES 92300472 T ES92300472 T ES 92300472T ES 2071428 T3 ES2071428 T3 ES 2071428T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
dioxo
acid
phenylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92300472T
Other languages
English (en)
Inventor
William Alvin Kinney
Deanna Colette Garrison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2071428T3 publication Critical patent/ES2071428T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)

Abstract

LA INVENCION SE REFIERE AL PROCESO DE PREPARACION DE COMPUESTOS DE LA FORMULA EN QUE: R ELEVADO 1, ES HIDROGENO, ALKYL O DE 1 A 6 ATOMOS DE CARBONO, O UN FENILALKIL DE 7 A 12 ATOMOS DE CARBONO; R (AL CUADRADO) , ES HIDROGENO, ALKIL DE 1 A 6 ATOMOS DE CARBONO, ALKENIL DE 2 A 6 ATOMOS DE CARBONO, O FENILALKIL DE 7 A 12 ATOMOS DE CARBONO. O R ELEVADO 1 Y R (AL CUADRADO) EN ASOCIACION SON Z, DONDE Z ES -CH SUB 2CH SUB 2-, CH SUB 2C(R ELEVADO 6)(R ELEVADO 7)CH SUB 2 ELEVADO 9)-C(R ELEVADO 10)(R ELEVADO 11)CH SUB 2ADO 6, R ELEVADO 8, R ELEVADO 10, SON INDEPENDIENTEMENTE, HIDROGENO, ALKIL DE 1 A 6 ATOMOS DE CARBONO, O HIDROXIL, Y R ELEVADO 7, R ELEVADO 9, Y R ELEVADO 11, SON INDEPENDIENTEMENTE HIDROGENO O ALKIL DE 1 A 6 ATOMOS DE CARBONO. A ES UN ALKILENE DE 1 A 6 ATOMOS DE CARBONO, O ALKENILENO DE 2 A 6 ATOMOS DE CARBONO; X ES CO SUB 2R ELEVADO 3, DONDE R ELEVADO 3 ES HIDROGENO O ALKIL DE 1 A 6 ATOMOS DE CARBONO, P(O)(OR ELEVADO 4)(OR ELEVADO 5) EN DONDE R ELEVADO 4 Y R ELEVADO 5, SON INDEPENDIENTEMENTE, HIDROGENO O ALKIL DE 1 ATOMOS DE CARBONO 3,5-DIOXO,1,2,4-OXADIAZOLIN-2 YL O 5-TETRAZOLYL. O UNA SAL FARMACEUTICAMENTE TOLERABLE CUYA COMPOSICION SEAN ANTONIMOS DE NMDA DE GRAN UTILIDAD COMO ANTICONVULSIVOS Y NEUROPROTECTORES EN SITUACIONES QUE CONLLEVAN UNA DESCARGA EXCESIVA DE AMINO ACIDOS EXCITANTES .
ES92300472T 1991-01-22 1992-01-20 Derivados de (((2-amino-3,4-dioxo-1-ciclobuten-1-il)amino)alquil)acido. Expired - Lifetime ES2071428T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64415791A 1991-01-22 1991-01-22
US07/806,861 US5168103A (en) 1991-01-22 1991-12-17 [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives

Publications (1)

Publication Number Publication Date
ES2071428T3 true ES2071428T3 (es) 1995-06-16

Family

ID=27094416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92300472T Expired - Lifetime ES2071428T3 (es) 1991-01-22 1992-01-20 Derivados de (((2-amino-3,4-dioxo-1-ciclobuten-1-il)amino)alquil)acido.

Country Status (23)

Country Link
US (2) US5168103A (es)
EP (1) EP0496561B1 (es)
JP (1) JP3167770B2 (es)
KR (1) KR100206055B1 (es)
AT (1) ATE119873T1 (es)
AU (1) AU639629B2 (es)
CA (1) CA2059704C (es)
CZ (1) CZ286407B6 (es)
DE (1) DE69201655T2 (es)
DK (1) DK0496561T3 (es)
ES (1) ES2071428T3 (es)
FI (1) FI105551B (es)
GR (1) GR3015456T3 (es)
HK (1) HK1005588A1 (es)
HU (2) HU215838B (es)
IE (1) IE65873B1 (es)
IL (1) IL100679A (es)
MX (1) MX9200240A (es)
NZ (1) NZ241330A (es)
RU (1) RU2039035C1 (es)
SK (1) SK280268B6 (es)
TW (1) TW211564B (es)
UA (1) UA27741C2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
KR970002653B1 (ko) * 1993-12-16 1997-03-07 엘지전자 주식회사 냉장고
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
EP0934257B1 (en) * 1996-07-17 2002-12-11 Wyeth Substituted n-arylmethylamino derivatives of cyclobutene-3,4-diones
US5763474A (en) * 1996-07-17 1998-06-09 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5846999A (en) * 1996-07-17 1998-12-08 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5750574A (en) * 1996-07-17 1998-05-12 American Home Products Corporation Fluorinated N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5780505A (en) * 1996-07-17 1998-07-14 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
ES2190091T3 (es) * 1997-08-01 2003-07-16 Wyeth Corp Procedimiento para la preparacion del acido (2-((8,9)-dioxo-2,6 diazabiciclo(5.2.0)-non-1(7)-en-2-2-il)-etil)fosfonico.
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
JPH1177971A (ja) * 1997-09-05 1999-03-23 Shinano Kenshi Co Ltd ブランケット胴及び該ブランケット胴を備えたオフセット印刷装置
ES2164040T3 (es) 1998-04-14 2008-02-01 The General Hospital Corporation Uso de d-serina o de d-alanina para el tratamiento de la esquizofrenia.
US6376555B1 (en) 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
US6166050A (en) * 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
KR100565008B1 (ko) * 2000-02-01 2006-03-30 주식회사유한양행 4-하이드라지노-3-사이클로부텐-1,2-다이온 유도체 및이들의 제조 방법
KR100742086B1 (ko) * 2001-07-27 2007-07-23 주식회사유한양행 4-페닐-3-사이클로부텐-1,2-다이온 유도체 및 그의 제조방법
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20050004079A1 (en) * 2003-04-09 2005-01-06 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
CN1863810B (zh) * 2003-04-09 2010-12-01 惠氏公司 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
TW200514775A (en) * 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
WO2005085197A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
CA2583114A1 (en) 2004-10-08 2006-04-20 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them
US20090061024A1 (en) * 2007-08-27 2009-03-05 Wyeth Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect
RU2515615C2 (ru) 2008-09-18 2014-05-20 Нортвестерн Юниверсити Модуляторы нмда-рецептора и их применения
MX2011009716A (es) 2009-03-19 2011-10-17 Wyeth Llc Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este.
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP2016506961A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CA2898774C (en) 2013-01-29 2021-07-13 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
WO2014120783A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2018229744A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518660A1 (de) * 1965-07-09 1969-08-14 Huels Chemische Werke Ag Verfahren zur Herstellung aminosubstituierter Dioxocyclobutene
GB1563090A (en) * 1975-07-31 1980-03-19 Smith Kline French Lab Cyclobutene-diones
US4390701A (en) * 1981-05-18 1983-06-28 Bristol-Myers Company 1-Amino-2-[3-(3-piperidinomethylphenoxy)propylamino]cyclobutene-3,4-dione
AU1956283A (en) * 1982-10-02 1984-04-05 Smith Kline & French Laboratories Limited 1-(3-(4-(substited aminomethyl)pyrid-2-yl-oxy)-prop-1-yl- amino) - 2-aminocyclobut-i-ene-3,4-diones
US4927970A (en) * 1987-05-14 1990-05-22 Bristol-Myers Company Substituted 3-cyclobutene-1,2-dione intermediates
US4902687A (en) * 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists

Also Published As

Publication number Publication date
IL100679A0 (en) 1992-09-06
TW211564B (es) 1993-08-21
NZ241330A (en) 1993-10-26
AU639629B2 (en) 1993-07-29
IL100679A (en) 1996-10-31
JP3167770B2 (ja) 2001-05-21
FI920261A0 (fi) 1992-01-21
HU215838B (hu) 2000-06-28
DE69201655D1 (de) 1995-04-20
HUT61970A (en) 1993-03-29
DK0496561T3 (da) 1995-05-22
FI105551B (fi) 2000-09-15
KR920014765A (ko) 1992-08-25
SK280268B6 (sk) 1999-10-08
CZ14492A3 (en) 1994-01-19
IE65873B1 (en) 1995-11-29
SK14492A3 (en) 1995-02-08
DE69201655T2 (de) 1995-07-13
EP0496561A3 (en) 1992-12-23
CA2059704A1 (en) 1992-07-23
HU211653A9 (en) 1995-12-28
FI920261A (fi) 1992-08-23
ATE119873T1 (de) 1995-04-15
RU2039035C1 (ru) 1995-07-09
IE920176A1 (en) 1992-07-29
JPH04321654A (ja) 1992-11-11
MX9200240A (es) 1994-03-31
CZ286407B6 (en) 2000-04-12
US5240946A (en) 1993-08-31
CA2059704C (en) 2002-07-16
KR100206055B1 (ko) 1999-07-01
EP0496561B1 (en) 1995-03-15
HK1005588A1 (en) 1999-01-15
UA27741C2 (uk) 2000-10-16
AU1030192A (en) 1992-07-30
GR3015456T3 (en) 1995-06-30
EP0496561A2 (en) 1992-07-29
HU9200192D0 (en) 1992-04-28
US5168103A (en) 1992-12-01

Similar Documents

Publication Publication Date Title
ES2071428T3 (es) Derivados de (((2-amino-3,4-dioxo-1-ciclobuten-1-il)amino)alquil)acido.
NO177301C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive N-(aryloksyalkyl)heteroarylpiperidiner og -heteroarylpiperaziner
PH17740A (en) Substituted acyl derivatives of 1-2,3,4 tetrahydro-isoquinoline-3-carboxylic acids,their pharmaceutical compositions and use
TW330202B (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
SE8201854L (sv) N-substituerade amino-aminosyror
TW357143B (en) Benzo[g]quinoline derivatives
ES8704955A1 (es) Un proceso para la produccion de un compuesto de cefalospo- rina
ES8801833A1 (es) Un procedimiento para la preparacion de un compuesto.
ATE230728T1 (de) Oral aktive eisen (iii) chelatoren
IL122664A0 (en) Esters and amides as PLA2 inhibitors
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
ES8801922A1 (es) Procedimiento para la fabricacion de un ester acido 1 beta-(2-(2-amino-4-tiazolil)alquenoilamino)-3-cefem-4-carboxilico.
DK173689D0 (da) Dicarboxylsyreamider
GB9305163D0 (en) Chemical compositions
ES8608517A1 (es) Dprocedimiento para preparar derivados de acido 4-hidroxi-3-quinoleino-carboxilico substituidos en posicion 2 con una funcion amino.
GB1494402A (en) Thienodiazepines
ES8702420A1 (es) Procedimiento para la obtencion de compuestos de aminoal- quilpenem
CA2111169A1 (en) Phenylacetic acid derivatives, process for the preparation thereof and corresponding use
BR1100549A (pt) Derivados de penem, processo para sua preparação, e, composições farmacêuticas.
NL7205885A (en) Benzocyclobutenyl-cephalosporins - useful as antibiotics
IT1192174B (it) Procedimento per produrre derivati di acido cefem-carbossilico e cefam-carbossilico
FR2399418A1 (fr) Procede de preparation d'acides iminoacetiques et nouveaux produits ainsi obtenus, utilises pour la synthese d'acides cepham- ou cephem-carboxyliques

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 496561

Country of ref document: ES